Association between Fas/FasL polymorphism and susceptibility to leukemia: A meta-analysis

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 3, 2015, Pages 3817-3824

  Chen, Yiran ^a   He, Yiho ^a   Lu, Xiaotong ^a   Zeng, Zhirui ^a   Tang, Chen ^a   Xue, Tongyuan ^b   Li, Yuhua ^b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Leukemia; Meta analysis; Polymorphism

Indexed keywords

ARTICLE; CELL HETEROGENEITY; ETHNICITY; FAS GENE; GENE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; LEUKEMIA; META ANALYSIS; SENSITIVITY ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84929380029     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Malek S. Molecular biomarkers in chronic lymphocytic leukemia. Adv Exp Med Biol 2013; 792: 193-214.
2. Satoh Y, Matsumura I, Tanaka H, Harada H, Harada Y, Matsui K, Shibata M, Mizuki M, Kanakura Y. C-terminal mutation of RUNX1 attenuates the DNA-damage repair response in hematopoietic stem cells. Leukemia 2012; 26: 303-11.
3. Inazawa J, Itoh N, Abe T, Nagata S. Assignment of the human Fas antigen gene (Fas) to 10q24.1. Genomics 1992; 14: 821-2.
4. Behrmann I, Walczak H, Krammer PH. Structure of the human APO-1 gene. Eur J Immunol 1994; 24: 3057-62.
5. Strasser A, Jost PJ, Nagata S. The many roles of FAS receptor signaling in the immune system. Immunity 2009; 30: 180-92.
6. Scholz M, Cinatl J. Fas/FasL interaction: a novel immune therapy approach with immobilized biologicals. Med Res Rev 2005; 25: 331-42.
7. Huang QR, Morris D, Manolios N. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol 1997; 34: 577-82.
8. Sibley K, Rollinson S, Allan JM, Smith AG, Law GR, Roddam PL, Skibola CF, Smith MT, Morgan GJ. Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res 2003; 63: 4327-30.
9. Wu J, Siddiqui J, Nihal M, Vonderheid EC, Wood GS. Structural alterations of the FAS gene in cutaneous T-cell lymphoma (CTCL). Arch Biochem Biophys 2011; 508: 185-91.
10. Kim HJ, Jin XM, Kim HN, Lee IK, Park KS, Park MR, Jo DY, Won JH, Kwak JY, Kim HJ, Choi JS, Juhng SW, Choi C. Fas and FasL polymorphisms are not associated with acute myeloid leukemia risk in Koreans. DNA Cell Biol 2010; 29: 619-24.
11. Gormus U, Ergen A, Yaylim-Eraltan I, Yilmaz H, Turna A, Bozkurt N, Isbir T. Fas-1377 A/G polymorphism in lung cancer. In Vivo 2007; 21: 663-6.
12. Wang M, Wu D, Tan M, Gong W, Xue H, Shen H, Zhang Z. FAS and FAS ligand polymorphisms in the promoter regions and risk of gastric cancer in Southern China. Biochem Genet 2009; 47: 559-68.
13. Wang W, Zheng Z, Yu W, Lin H, Cui B, Cao F. Polymorphisms of the FAS and FASL genes and risk of breast cancer. Oncol Lett 2012; 3: 625-628.
14. Nunobiki O, Ueda M, Toji E, Yamamoto M, Akashi K, Sato N, Izuma S, Torii K, Tanaka I, Okamoto Y, Noda S. Genetic Polymorphism of Cancer Susceptibility Genes and HPV Infection in Cervical Carcinogenesis. Patholog Res Int 2011; 2011: 364069.
15. Lima L, Morais A, Lobo F, Calais-da-Silva FM, Calais-da-Silva FE, Medeiros R. Association be tween FAS polymorphism and prostate cancer development. Prostate Cancer Prostatic Dis 2008; 11: 94-8.
16. Tong N, Zhang L, Sheng X, Wang M, Zhang Z, Fang Y, Xue Y, Li J, Zhang Z. Functional polymorphisms in FAS, FASL and CASP8 genes and risk of childhood acute lymphoblastic leukemia: a case-control study. Leuk Lymphoma 2012; 53: 1360-6.
17. Valibeigi B, Amirghofran Z, Golmoghaddam H, Hajihosseini R, Kamazani FM. Fas Gene Variants in Childhood Acute Lymphoblastic Leukemia and Association with Prognosis. Pathol Oncol Res 2013; [Epub ahead of print].
18. Geng P, Li J, Ou J, Xie G, Wang N, Xiang L, Sa R, Liu C, Li H, Liang H. Association of fas -1377 g/a polymorphism with susceptibility to cancer. PLoS One 2014; 9: e88748.
19. Wang X, Xing GH, Fan CC. Association between the FAS rs2234767G/A polymorphism and cancer risk: a systematic review and meta-analysis. DNA Cell Biol 2014; 33: 320-7.
20. Xu Y, He B, Li R, Pan Y, Gao T, Deng Q, Sun H, Song G, Wang S. Association of the polymorphisms in the Fas/FasL promoter regions with cancer susceptibility: a systematic review and meta-analysis of 52 studies. PLoS One 2014; 9: e90090.
21. Cochran WG. The combination of estimates from different experiments. Biometrics 1954; 10: 101-129.
22. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-60.
23. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-48.
24. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.
25. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34.
26. Farre L, Bittencourt AL, Silva-Santos G, Almeida A, Silva AC, Decanine D, Soares GM, Alcantara LC Jr, Van Dooren S, Galvão-Castro B, Vandamme AM, Van Weyenbergh J. Fas 670 promoter polymorphism is associated to susceptibility, clinical presentation, and survival in adult T cell leukemia. J Leukoc Biol 2008; 83: 220-2.
27. Rozenfeld-Granot G, Toren A, Amariglio N, Brok-Simoni F, Rechavi G. Fas gene polymorphisms in chronic myeloid leukemia. Exp Hematol 2001; 29: 228-33.
28. Rollinson S, Allan JM, Law GR, Roddam PL, Smith MT, Skibola C, Smith AG, Forrest MS, Sibley K, Higuchi R, Germer S, Morgan GJ. High-throughput association testing on DNA pools to identify genetic variants that confer susceptibility to acute myeloid leukemia. Cancer Epidemiol Biomarkers Prev 2004; 13: 795-800.